Project Grant R01CA311275
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $390K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40506, USA
Similar Awards
- The National Cancer Institute of the Department of Health and Human Services awarded The University of Kentucky Research Foundation $499,316 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize the role and regulation of HIVEP2 in tumor immune evasion in triple-negative breast cancer. The research investigates how HIVEP2, a zinc finger protein, drives immune evasion by promoting expression of interleukin-four induced gene 1 (IL4I1) and programmed cell...
- The National Cancer Institute awarded The University of Kentucky Research Foundation $281,820 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to plan a future intervention trial improving clinical trial education and enrollment for cancer patients. The planning grant supports development of an intervention designed to address persistently low cancer trial enrollment rates in the United States. The award funds preparatory work for a future randomized...
- The National Cancer Institute awarded the University of Kansas Medical Center Research Institute, Inc. $398,544 on April 8, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct pre-clinical evaluation of a highly selective SMARCA2 degrader in therapy-resistant triple-negative breast cancer. The research addresses mechanisms of resistance to neoadjuvant systemic therapy in triple-negative breast cancer patients with residual disease. The project leverages the recipient's...
- The National Cancer Institute awarded The University of Kentucky Research Foundation $395,973 on June 9, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394, Assistance Listing designation R21CA307890) to conduct single-cell-resolution imaging research on drug resistance mechanisms in non-small cell lung cancer patient tumor microenvironments, with emphasis on the interaction between toxic metal pre-exposure and therapeutic resistance in Appalachian populations. The...
- The National Cancer Institute awarded The University of Kentucky Research Foundation $154,000 on June 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to support research on fatty acid synthase-driven exosome secretion in colorectal cancer metastasis. The project investigates the role of fatty acid synthase (FASN) in promoting exosome secretion by colorectal cancer cells and the contribution of these exosomes to pre-metastatic niche formation in the liver. The research...
- Federal Project Grant Award Summary The National Cancer Institute awarded $399,829 to the University of North Carolina at Chapel Hill under the Cancer Biology Research program (CFDA 93.396) for a two-year project (September 1, 2025–August 31, 2027) investigating the role of Fusobacterium nucleatum in breast cancer progression and therapeutic resistance. The research will characterize how this bacterium, detected in approximately 30% of breast cancer cases, alters the tumor microenvironment and...
- The National Cancer Institute, a division of the National Institutes of Health under the Department of Health and Human Services, awarded $134,000 to the University of Massachusetts Medical School on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The recipient will conduct research employing genetically engineered mouse models to elucidate mechanisms by which loss of CAMK2B (calcium/calmodulin-dependent protein kinase II beta) promotes metastasis and immune...
- The National Cancer Institute awarded Vanderbilt University $119,735 on January 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on neutrophil-driven pro-recurrent niche formation in mammary adipose tissue following radiation therapy for triple negative breast cancer. The research tests the hypothesis that neutrophils facilitate formation of a pro-recurrent niche in irradiated mammary adipose tissue through release of pro-inflammatory proteins and...
- The National Cancer Institute awarded the University of Tennessee Health Science Center $389,215 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop selective N-glycan biosynthesis inhibitors targeting metastatic triple-negative breast cancer. The research employs structure-guided medicinal chemistry to optimize DPAGT1 (dolichyl-phosphate N-acetylglucosaminephosphotransferase 1) inhibitors, the first committed enzyme in N-glycan biosynthesis. The project...
- The National Cancer Institute awarded the University of Massachusetts $2.736 million on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop multimodal microbial therapies for treating triple negative breast cancer resistant to immune checkpoint inhibitors. The award funds research to engineer microbial therapies that deliver therapeutics into cancer cells, deploy oncolytic viruses, and target radiation to tumors, with the goal of generating durable antitumor...